Q4 2025 Novocure Ltd Earnings Call Transcript
Key Points
- NovoCure Ltd (NVCR) achieved a record $655 million in net revenues for 2025, marking an 8% increase from 2024.
- The company received FDA approval for Optune Pax for the treatment of locally advanced pancreatic cancer, with regulatory filings also submitted in Europe and Japan.
- NovoCure Ltd (NVCR) presented final data from two large randomized trials at major medical congresses, followed by publications in leading medical journals.
- The company anticipates several national or regional launches of its products, including Optune Gio in Spain, Czechia, and British Columbia, and Optune Lua in Japan.
- NovoCure Ltd (NVCR) issued annual net revenue guidance for 2026, projecting growth between 3% and 8%, and aims to achieve adjusted EBITDA breakeven.
- The Optune Lua launch has been slower than originally projected in the US and Germany, leading to a right-sizing of marketing spend.
- NovoCure Ltd (NVCR) experienced a decrease in gross margin to 75% for the full year 2025, down from 77% in 2024, due to increased costs and decreased prior-period collections.
- The company reported a net loss of $136 million for the full year 2025, with a loss per share of $1.22.
- NovoCure Ltd (NVCR) faced a temporary halt in Medicare billing privileges due to an administrative issue, although it was resolved without impacting revenue recognition.
- The resignation of Dr. Nicolas Leupin, Chief Medical Officer, led to a reorganization of the scientific and clinical teams, which may impact R&D execution.
Good day and thank you for standing by. Welcome to the Novocure fourth-quarter 2025 earnings call.
(Operator Instructions)
Please be advised that today's conference is being recorded.
I'd now like to hand the conference over to Adam Daney, Head of Investor Relations. Please go ahead.
Good morning and thank you for joining us to review Novocure's fourth-quarter and full-year 2025 performance.
I'm joined on the phone today with our Executive Chairman, Bill Doyle; CEO, Frank Leonard; and CFO, Christoph Brackmannn. Other members of our executive leadership team will be available for Q&A.
For your reference, slides accompanying this earnings release can be found on our website www.Novocure.com on the Investor Relations page under quarterly reports.
Before we start, I would like to remind you that our discussions today during this conference call will include forward-looking statements,
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
